Status:
UNKNOWN
Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
National Science and Technology Council, Taiwan
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18+ years
Brief Summary
The aims of this three-year study are to explore symptom experience and its related factors for the patients with chronic hepatitis C Infection receiving interferon-α with ribavirin for 24 weeks and f...
Detailed Description
The antiviral treatment, interferon-α with ribavirin, has been used in treating chronic hepatitis C patients to prevent the development of liver cirrhosis and hepatocellular carcinoma. However, the du...
Eligibility Criteria
Inclusion
- patients with Chronic Hepatitis C Infection Receiving 24-week Interferon-α with Ribavirin Treatments
- Those Who willing to participate in the research
- Aged above 18
Exclusion
- None
Key Trial Info
Start Date :
September 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2011
Estimated Enrollment :
390 Patients enrolled
Trial Details
Trial ID
NCT01178749
Start Date
September 1 2007
End Date
July 1 2011
Last Update
August 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan